ISA's drug ISAtx247 has a broad therapeutic window and apparently early results in Phase II human psoriasis and renal transplant trials are going extremely well, confirming ISAtx247's potential for use in multiple autoimmune indications and to become the gold standard for preventing transplant rejection. This is looking more and more like a "blockbuster" in the making.
Isotechnika Makes Scientific Presentation At The 2002 American Transplant Congress In Washington, D.C.
14:00 GMT-04:00 Tuesday, April 30, 2002
Trades on Toronto Stock Exchange Symbol - (ISA - (TSE:ISA)
EDMONTON, April 30 /CNW/ - Dr. Randall Yatscoff, President and COO of Isotechnika Inc. reports that Dr. Launa Aspeslet, the company's Vice-President of Regulatory Affairs and Quality Assurance presented a paper entitled "Phase 2 Trial Results of ISA(TX)247, A Novel Calcineurin Inhibitor, in Renal Transplantation" today at the American Transplant Congress. This educational event has become one of the premier international meetings in the field of basic and clinical transplantation science and medicine. Leading world experts, scientists, scholars and clinicians have gathered in Washington to eview and evaluate the latest clinical and basic science advances in transplantation science, medicine and surgery.
"Our selection to present and share the preliminary results from our Phase II renal transplant clinical trails of ISA(TX)247 at this important international congress is a great privilege and an honor for our company and its scientific team" states Dr. Yatscoff. "This independent recognition by our peers provides further validation of our drug development program and confirmation of the high level of global interest in ISA(TX)247 and its significant potential to become one of the leading immunosuppressive therapies in the prevention of organ rejection of transplant recipients."
About Isotechnika Inc.
Isotechnika Inc. and Roche recently signed an agreement for the global co-development and commercialization of Isotechnika's innovative transplant drug, ISA(TX)247. This agreement represents the largest Canadian drug development deal between a large pharma and a biotech company. Isotechnika Inc. is an international life sciences company headquartered in Edmonton, Alberta with additional operations in Arizona. The company is focused on the development of immunosuppressive therapeutic drugs for use in organ transplant patients and in the treatment of autoimmune diseases. Its founders and scientific team have developed a novel, multi-platform drug, ISA(TX)247, which has progressed through discovery, pre-clinical and Phase 1 human clinical trials in less than five years. ISA(TX)247 is currently undergoing Phase 2 human clinical trials in renal transplantation and psoriasis and has the potential to become the market leader in immunosuppressant therapy; an established market for drugs of this class is in excess of 2.2 billion USD per year globally. Isotechnika Inc. is a TSE 300 Index Company publicly traded under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.
For further information: Gordon Agopsowicz, Director, Investor Relations, Isotechnika Inc., (780) 487-1600 Ext. 245, (780) 484-4105 (fax), gagopsowicz@isotechnika.com, www.isotechnika.com; Archived images on this organization are available through CNW E-Pix at newswire.ca.. Images are free to members of The Canadian Press. |
